Good planning makes any long-term health routine easier to manage. Staying organized from the beginning can reduce stress, help you recognize changes over time, and provide useful information to discuss with your healthcare provider.

Before beginning any medication or supplement, discuss it with your physician or another qualified healthcare professional. If you and your provider decide to move forward, follow the dosage and schedule they recommend. Taking medication consistently and exactly as directed helps reduce the risk of dosing errors.

Keep a Daily Journal

Purchase a notebook or create a digital journal dedicated to your health routine. If you expect to follow a protocol for several months, keeping detailed records can help you monitor your progress and identify trends that might otherwise go unnoticed.

Consider recording the following information each day:

Protocol

• Days on:

• Days off:

Medication

• Brand:

• Date:

• Time taken:

• Amount:

• Form (powder, paste, capsule, etc.):

Food & Drink

• Before taking medication:

• During:

• After:

Supplements

If you are taking vitamins or other supplements, record:

• Supplement name:

• Brand:

• Amount:

• Time taken:

• Taken with food?

• Consumed with or added to:

Water Intake

Staying hydrated is important for overall health. Record:

• Total glasses of water consumed each day

• Times you drank water

• Water consumed with meals

• Water consumed with medication

• Water consumed with supplements

Daily Health Report

Take a few minutes each day to write down how you feel.

• How do I feel today compared to yesterday?

• How do I feel compared to the first day?

• What changes have I noticed?

• Pain level:

• Energy level:

• Sleep quality:

• Digestive symptoms:

• Other observations:

Tracking Your Health

Some people and their healthcare providers use periodic laboratory testing to monitor general health while taking long-term medications. Depending on your individual circumstances, your provider may recommend tests that evaluate blood counts, liver function, kidney function, inflammation, or other biomarkers.

Examples include:

• Complete Blood Count (CBC)

• Comprehensive Metabolic Panel (CMP)

• High-sensitivity C-reactive protein (hs-CRP)

• Liver function testing

In many areas, certain laboratory tests can also be ordered directly through consumer laboratory services without a physician’s order, although availability varies by location.

Examples include:

• Labcorp OnDemand

• QuestHealth

• Request A Test

Some services also offer access to specialty laboratory tests, including certain tumor marker tests, when appropriate and ordered.

Stay Organized

Your journal becomes a valuable record of your health over time. Recording symptoms, laboratory results, medications, supplements, and other observations creates a timeline that can help you and your healthcare provider evaluate how your body is responding and determine whether changes to your treatment plan are appropriate.

The more consistent your records, the more useful they become. Whether you continue your routine for several weeks or several months, you’ll have a detailed history to reference during future medical appointments and when reviewing your progress.

This is not medical advice. Please discuss all blood tests with your doctor before visiting any lab.

Lab blood tests

• Cancer Antigen CA 19-9

• Cancer Antigen CA 15-3

• Amylase Isoenzymes

• Cancer Antigen CA 125

• Cancer Antigen CA 27.29

• CEA (Carcinoembryonic Antigen)

The first five are tumor markers (proteins that certain cancers shed into the bloodstream), and the last one, amylase isoenzymes, is a source-identification test.

CA 19-9
A carbohydrate antigen most linked to pancreatic cancer, and also to bile duct, gallbladder, gastric, and colorectal cancers. Used for gauging prognosis, assessing whether a pancreatic tumor is likely resectable, and monitoring response to treatment. Two important quirks: anything obstructing the bile ducts (stones, cholangitis, even benign jaundice) can push it very high without cancer, and roughly 5–10% of people lack the Lewis blood group enzyme needed to make it at all, so their level stays low no matter what.

CA 15-3
A fragment of the MUC1 protein shed by breast cancer cells. It’s a monitoring marker for advanced or metastatic breast cancer — following whether treatment is working or disease is progressing. It’s usually normal in early-stage breast cancer, which is why it isn’t used for screening or diagnosis. Benign breast conditions, liver disease, and other cancers can also elevate it modestly.

CA 27.29
Also a MUC1 marker — essentially the same antigen as CA 15-3, detected with a different antibody. It serves the same purpose in breast cancer monitoring, and the two are largely interchangeable. Labs typically run one or the other; having both ordered is usually redundancy rather than two different pieces of information.

CA 125
The MUC16 protein, best known in epithelial ovarian cancer. It’s used to monitor treatment response and recurrence, and as one input (often alongside HE4 and imaging) when evaluating an ovarian or pelvic mass. It’s notably nonspecific in premenopausal women — endometriosis, fibroids, menstruation, pregnancy, pelvic infection — and rises with anything irritating the peritoneum or causing fluid buildup, including cirrhosis and heart failure. It’s more meaningful in postmenopausal women.

Amylase isoenzymes
This one answers a different question. Total amylase in blood comes mainly from two sources: the pancreas (P-type) and the salivary glands (S-type). Fractionating it tells you which. It’s ordered when amylase is elevated, but the cause isn’t obvious — to confirm a pancreatic source (pancreatitis, pancreatic duct obstruction) versus a salivary one (mumps, parotitis, heavy alcohol use, purging behaviors). It also identifies macroamylasemia, a harmless condition where amylase binds to an antibody and can’t be cleared by the kidneys, producing persistently high readings with no disease at all. Occasionally, certain lung and ovarian tumors produce salivary-type amylase ectopically, which is likely why it appears in a panel like this.

CEA (carcinoembryonic antigen)
A glycoprotein made abundantly by fetal gut tissue and normally present at very low levels in adults. It’s most associated with colorectal cancer but also rises in pancreatic, gastric, lung, breast, and medullary thyroid cancers. Its main real value is tracking: a baseline before surgery, then serial measurements afterward, where a rising trend can signal recurrence months before imaging does. It’s also raised by non-cancer things — smoking is a common one, along with cirrhosis, inflammatory bowel disease, pancreatitis, and COPD.

The framing that matters most: none of these are diagnostic on their own, and none are approved as screening tests for people without symptoms. They’re too easily raised by benign conditions and too often normal in early cancer. Their strength is in trends over time in someone with a known diagnosis, and as supporting evidence alongside imaging, exam findings, and ultimately tissue. A single elevated value is a prompt to look further, not an answer. Reference ranges also vary by lab and assay, so results should be compared against the range printed on your own report and ideally followed at the same lab.

Labcorp OnDemand - https://www.ondemand.labcorp.com/products www.labcorp.com

QuestHealth.com - https://www.questhealth.com/shop-tests www.questhealth.com/

Request A Test - https://requestatest.com/tests/search?criteria=cancer

https://requestatest.com/

https://tylerfowler.com/ https://www.gofundme.com

This young man and his family can use some help. Ty, his parents Rick and Lindsay, and their entire family have been navigating a world of specialists, scans, biopsies, hospital stays, treatments, and difficult decisions. Please check out his story and help where you can.

Through it all, Ty continues to show the same joy, courage, and resilience that have always defined him. Your financial support, prayers, and sharing Ty's story are deeply appreciated.

Continue Praying for Tyler

As Ty continues treatment, our family remains grateful for every prayer, message, and word of encouragement. We believe God is at work through every step of this journey, and we invite you to continue standing with Ty and his family in prayer.

Healing & Recovery

Pray that Ty’s treatments are effective and that his body continues to respond well.

Wisdom For His Care Team

Pray for wisdom and discernment for Ty’s doctors, specialists, and care team.

Peace & Strength

Pray for peace, endurance, and provision for Ty, Rick, Lindsay, and the entire family.

https://tylerfowler.com/ https://www.gofundme.com

Based on the provided sources, fenbendazole (FBZ) induces pyroptosis—a highly inflammatory form of programmed cell death—in breast cancer cells through the p53/HK2/caspase-3/GSDME signaling pathway.

Here is the step-by-step breakdown of this mechanism:

1. Inhibition of Glycolysis via the p53/HK2 Axis

Fenbendazole targets the metabolic reprogramming of breast cancer cells by acting on the p53-glycolysis axis. FBZ significantly upregulates the p53 tumor suppressor protein, which subsequently downregulates the expression of several critical glycolytic enzymes. The most potent inhibition occurs with Hexokinase 2 (HK2), a critical enzyme for tumor metabolism. By inhibiting HK2, fenbendazole severely suppresses aerobic glycolysis, resulting in reduced glucose consumption, decreased lactate production, and lowered ATP (energy) levels in the cancer cells.

2. Activation of Caspase-3 and GSDME

The disruption of glycolysis and the inhibition of HK2 serve as a trigger that activates the caspase-3/GSDME cascade. Fenbendazole treatment significantly activates caspase-3. Once activated, cleaved caspase-3 acts on Gasdermin E (GSDME), cleaving it into its active N-terminal fragment (GSDME-NT).

3. Membrane Pore Formation and Morphological Changes

The newly formed active GSDME fragments drive the execution phase of pyroptosis by forming pores in the cell membrane. This causes the breast cancer cells to undergo hallmark pyroptotic morphological changes, including severe cell swelling, membrane rupture, and the formation of large blisters.

4. Release of Pro-Inflammatory Cytokines

As the cell membrane is ruptured by GSDME pores, the dying cancer cells rapidly release intracellular contents into the surrounding microenvironment. This includes a significant release of lactate dehydrogenase (LDH) and mature pro-inflammatory cytokines, specifically IL-18 and IL-1β.

A Note on Cell Death Plasticity

Researchers found that GSDME is the key trigger for this specific type of cell death. When GSDME is deliberately knocked down or silenced in laboratory settings, the release of inflammatory markers (LDH, IL-18, IL-1β) drops significantly. Interestingly, turning off this pyroptotic pathway does not stop fenbendazole from killing the breast cancer cells; instead, the drug demonstrates “plasticity” by compensating and triggering standard apoptosis (non-inflammatory cell death) to eliminate the tumor cells.

Some anticancer drugs (vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel) also display a similar mechanism of action, suggesting that fenbendazole could have anticancer activity. Studies on the antitumor effect of fenbendazole have supported this theory. *https://www.sciencedirect.com/science/article/pii/S2468294222000910

Vlachou, I., Parsonidis, P., Mamagkaki, A., Bouris, I., & Papasotiriou, I. (2022). Teaching an old dog new tricks: The case of Fenbendazole. Cancer Treatment and Research Communications, 32, 100601. https://doi.org/10.1016/j.ctarc.2022.100601

Fenbendazole, originally designed to cure parasites, selectively blocks microtubule synthesis by binding to β-tubulin. This action stops the polymerization of tubulin dimers in parasite cells, leading to their death. Surprisingly, fenbendazole, along with other benzimidazoles, exhibits similar effects against tumor cells. Today, it is believed that fenbendazole kills cancer through three main mechanisms:

1. Apoptosis Induction

Fenbendazole’s anti-tumor effect is thought to occur through its interaction with β-tubulin, leading to cell cycle arrest and cytotoxicity. The inhibition of tubulin polymerization into microtubules by benzimidazole carbamates in both helminths and human tumor cells is well documented.

*https://www.fenbendazole.org/fenbendazole-information/how-fenbendazole-works/

[(A-pop-TOH-sis) A type of cell death in which a series of molecular steps in a cell lead to its death. This is one method the body uses to get rid of unneeded or abnormal cells. The process of apoptosis may be blocked in cancer cells. Also called programmed cell death.]

*https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apoptosis

When administered orally at micromolar concentrations, fenbendazole induces cytotoxicity and effectively blocks cancer cell growth. Fenbendazole also causes oxidative stress and activates the MEK3/6-p38MAPK pathway, inhibiting cancer cell proliferation and enhancing apoptosis. Fenbendazole reduces toxicity to normal cells while maintaining its anti-cancer effects of impairing energy metabolism and restraining cancer cell migration and invasion (37).

*https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf

Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Res. 2024;44(9):3725-3735. doi:10.21873/anticanres.17197

Animal testing shows that after hepatic metabolism, fenbendazole and its metabolites are excreted via the feces and urine.

Stay positive. Think happy thoughts.

Our thoughts are the most powerful tool we have to heal.

Dr. Masaru Emoto, a Japanese researcher, studied the formation of ice crystals and snowflakes and found that the snowflakes, even though they are made from pure water, reacted differently to classical music and kind words such as ‘thank you.’

The ice crystals formed into beautiful patterns when treated with kindness and gentle music. But if the water molecules were subjected to negative thoughts, harsh words, and loud music, the snowflakes were distorted and didn’t form properly.

Dr. Masaru Emoto’s “snowflake experiment” suggests that human consciousness, emotions, and words can physically alter the molecular structure of water. By exposing water to positive intentions (e.g., “love,” “gratitude,” classical music) and freezing it, he claimed beautiful, hexagonal crystals formed, while negative, harsh, or chaotic input resulted in disorganized, distorted shapes.

Some dismissed it as pseudoscience and called him a fraud. However, we know that positive words, thoughts, and actions change your emotional state. Think positive! Every morning, tell yourself, “I’m healthy, I feel better, and each day I grow stronger.”

This is a Phase II clinical study launching this summer at the University of Florida. It is evaluating how the drug ivermectin works when combined with immune-checkpoint inhibitors (a type of treatment that helps the body’s immune system fight cancer) in adult patients with advanced solid tumors. [1, 2, 3]

Quick Facts About the ICONIC Trial

• Status: Actively preparing to recruit up to 80 patients.

• What it Does: Tests different dosing strategies of ivermectin given alongside standard immunotherapy.

• Why it Matters: Researchers want to see whether the drug can safely modify the immune system to make cancer treatments more effective.

• Track the Trial: You can review the full study rules, goals, and future locations on the ClinicalTrials.gov Study NCT07487805 page. [1, 2, 3, 4, 5]

There are additional characteristics that make fenbendazole a remarkable anti-cancer strategy and cancer-fighting tool.

What’s interesting, cancer cells cannot evade this de-wormer drug and adapt to its presence. This means that it can be taken constantly and remain effective. Unfortunately, advanced cancer can develop chemo-resistance to many chemotherapy and biological therapy medications, making them ineffective in time.

One of the main mechanisms of chemo-resistance in cancer cells is the adaptation of excreting the anti-cancer drugs to the outside via special drug efflux pumps called P-glycoproteins. Fenbendazole is not a target for p-glycoproteins, so it cannot be excreted out of cancer cells once it gets inside.

Therefore, the tumors don’t develop resistance against fenbendazole. It will still remain effective and kill cancer cells, which does not seem to be the case with a lot of chemotherapy drugs once chemo-resistance is developed. *https://www.nature.com/articles/s41598-018-30158-6

...

Fenbendazole could sensitize tumors to radiotherapy.

The dog-dewormer could be a considerable option before and during radiation treatment. It sensitizes the cancer cells to the treatment in a similar way like chemotherapy agents from the taxane group. *https://www.nature.com/articles/s41598-018-30158-6

The website Fenbendazole.org has some nice, easy-to-understand info and graphics on how fenbendazole works.

https://www.fenbendazole.org/fenbendazole-information/how-fenbendazole-works/

p53

Activating p53, a tumor suppressor gene.

3. Reactivation of the p53 Gene

This mechanism is still controversial, and more studies are needed to confirm that fenbendazole causes this action. However, an increasing number of studies suggest that fenbendazole might enhance the activity of p53, the strongest tumor suppressor in our bodies.

Interestingly, elephants have 20 copies of the p53 gene in their genome, while humans have only one. This might explain why elephants get cancer less frequently than humans, despite having larger bodies, more cells, and a higher potential for genetic mutations. However, there is an increasing number of studies that confirm the fact that fenbendazole might truly increase the strongest tumor suppressor in our bodies.

Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152. Published 2019 Jun 7. doi:10.3390/molecules24112152 *https://pubmed.ncbi.nlm.nih.gov/31181622/

Tumor cell lines with wild-type p53 show enhanced sensitivity to FZ induced apoptosis.

…

Simultaneously, it[fenbendazole] caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, expression of GLUT transporters as well as hexokinase (HK II) - a key glycolytic enzyme that most cancer cells thrive on. It blocked the growth of human xenografts in nu/nu mice model when mice were fed with the drug orally. The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity and may be evaluated as a potential therapeutic agent because of its effect on multiple cellular pathways leading to effective elimination of cancer cells.

…

These results suggest that FZ inhibits tumor cell growth in vivo by inducing apoptosis of tumor cells. When tumor sections were further examined for p53 protein expression, a number of p53 positive tumour cells were visible in FZ treated mice suggesting p53 induced cell death (Fig. 9h ii & v). Moreover, FZ treated A549 tumours showed very few CD31 positive endothelial cells in xenografts (Fig. 9h iii & vi). These data are in good agreement with our in vitro analysis of FZ mediated cell death.

*Scientific Reports Published online: 09 August 2018 https://www.nature.com/scientificreports

1. Introduction: The Power of Recycling in Medicine

In the high-stakes arena of oncology, the most formidable adversary is not the initial tumor, but the cancer that has learned to survive. For patients with advanced prostate cancer, the transition to a hormone-refractory or chemo-resistant state often signals a dead end for conventional medicine. When standard taxane-based therapies fail, the disease becomes increasingly aggressive, frequently migrating to the bone and lungs.

However, a breakthrough from researchers at Children’s Hospital Boston suggests that the next generation of cancer-fighting weapons might not be a multi-billion dollar “miracle drug,” but rather a class of inexpensive, existing medications sitting on pharmacy shelves. This is the “recycled drug” approach—leveraging FDA-approved medications for entirely new indications. Their surprising finding? Common anti-parasitic medications, typically used to treat worm infestations, may be the key to dismantling the most metastatic forms of human cancer.

2. The “Worm Medicine” Surprise: Repurposing Benzimidazoles

The journey to this discovery began with a massive, unbiased screen of 1,120 existing drugs. The goal was to identify compounds that could selectively kill aggressive cancer cells without the toxicity associated with traditional chemotherapy. Among the high-performing “hits” were medications like clofazimine (used for leprosy), fluspirilene (an anti-psychotic), niclosamide, and suloctidil.

But the standout candidates belonged to a class of anti-helminthic agents known as benzimidazoles, specifically Albendazole and Fenbendazole & Mebendazole. These drugs have been used for decades to treat parasitic infections in both humans and animals by disrupting the internal “scaffolding” of the parasites. For oncologists, the appeal of these “recycled drugs” is immense: because they are already approved for human use, they come with established safety profiles and known drug administration regimens, potentially shaving years off the clinical trial process.

3. Targeting the “Worst of the Worst” Cells

What makes this research particularly rigorous is the use of “Phenotype-Based Screening.” The team didn’t just look for drugs that kill cancer; they looked for drugs that killed only the highly metastatic cells. They tested the drugs against matched pairs of cancer lines: the highly aggressive PC-3MLN4 variant versus its less mobile parental line, PC-3M, as well as the Dunning rat AT6.1 model.

The study revealed a phenomenon of selective cytotoxicity. These drugs were significantly more potent against the aggressive variants than the original tumor cells. This suggests that as cancer cells evolve to become more dangerous, they actually develop new biological “Achilles’ heels.”

“During the evolution of metastatic progression, these cells may also acquire vulnerabilities or susceptibility to certain agents. We hypothesized that such vulnerabilities could be targeted in developing effective agents for treatment of metastatic prostate cancer.”

Researchers suggest these vulnerabilities may be linked to metastatic cells acquiring stem cell properties, thereby making them uniquely sensitive to the microtubule-disrupting action of benzimidazoles.

4. When Standard Chemo Fails: The Paclitaxel Connection

The most striking finding involves patients who have developed resistance to taxanes, the standard chemotherapy for advanced prostate cancer. In a phenomenon researchers call a “requirement for optimal growth,” some paclitaxel-resistant cells (like the PC-3TxR line) actually began growing faster when exposed to more paclitaxel.

Benzimidazoles, however, remained devastatingly effective against these resistant cells. In fact, they were more potent against the resistant lines than the sensitive ones. For instance, Fenbendazole showed an ED_{50} of 1.82 \muM in sensitive PC-3 cells, but that number dropped to a significantly more potent 0.44 \muM in the paclitaxel-resistant PC-3TxR cells.

The reason for this success lies in a “precision bypass” of the cancer’s defense system. While both drugs target microtubules, they bind to different sites on the tubulin protein. While taxanes bind near the intradimer interface facing the microtubule lumen (the inside), benzimidazoles bind to sites on the outside of the microtubule. By attacking the cell’s structural integrity from a different angle, these drugs render the cancer’s hard-won resistance to standard chemo irrelevant.

5. A Shield for the Skeleton: Inhibiting Bone Destruction

Metastatic prostate cancer is notorious for its affinity for bone, leading to osteolysis—the painful destruction of bone tissue. To simulate this, researchers injected PC-3MLN4 cells directly into the tibias of mice.

The results of Albendazole treatment were visually stunning. While untreated subjects exhibited extensive bone resorption, the treated mice maintained their bone integrity. Using advanced X-ray and micro-CT imaging, the team confirmed that Albendazole significantly inhibited the cancer’s ability to destroy the skeleton. Beyond just killing the tumor, the drug acted as a protective shield for the bone microenvironment, reducing the cell proliferation index (Ki-67) and inducing massive apoptosis (cell death) within the bone lesions.

6. The Nanotechnology Bridge: Solving the Solubility Problem

Despite the promise, there was a significant technical hurdle: benzimidazoles are highly hydrophobic, meaning they do not dissolve well in water or blood. To translate this from the lab to the clinic, the team had to solve the bioavailability problem.

They developed two primary delivery systems:

• DNTC Solvent: A stabilization “cocktail” consisting of DMSO, N-methyl-2-pyrrolidone (NMP), Tween-80, and Cremophor EL in a 1:3:2:2 ratio. This formulation achieved a greater than 10-fold increase in the plasma levels of the drug compared to standard preparations.

• PLGA-PEG Nanoparticles: Recognizing that the organic solvents in DNTC are less feasible for human systemic use, they engineered nanotechnology-based particles. These nanoparticles further increased cytotoxicity and significantly extended survival in animal models even at lower doses.

“Our studies strongly suggest that it is feasible to identify novel and effective therapeutic agents from a multi-stages, phenotype-based screening of known drugs, and through improvisation of the pre-existing pharmacological knowledge, we may be able to find immediate novel uses for these agents.”

7. Conclusion: A New Horizon for Advanced Cancer Care

The discovery that Albendazole—a drug already used in humans with a relatively benign safety profile—could potentially outperform or supplement current chemotherapy marks a potential paradigm shift in oncology. These findings offer a beacon of hope for patients with late-stage, metastatic disease who have exhausted their options.

While clinical trials are the necessary next step, the message from the lab is clear: we may not always need to invent new molecules to solve old problems. Is it possible that the next great medical breakthrough for the “worst of the worst” cancers is already sitting on our pharmacy shelves, hidden in plain sight?

Source research: https://apps.dtic.mil/sti/tr/pdf/ADA545657.pdf and yes, this paper is from 2011.

Cancer cells rely on glucose as their main fuel. They absorb it faster than normal cells, so reducing glucose may slow their growth and help eliminate them. I believe, based on the science, this is how fenbendazole works.

Monitoring is crucial, with regular assessments of blood levels for vitamins and minerals to ensure safety and efficacy.

A Keto diet may be worth considering.

Share

Inhibition of Glucose Uptake in Cancer Cells

Malignant cells exhibit elevated glucose uptake, consuming glucose at up to 200 times the rate of normal cells via aerobic glycolysis (the Warburg effect). This phenomenon is detected on PET scans, where regions with greater glucose uptake often correspond to cancerous tumors or inflammatory sites.

Fenbendazole limits cancer cell fueling in several ways:

It decreases the expression of glucose transporter proteins (GLUTs), which mediate glucose entry into cancer cells from the bloodstream.

Additionally, it inhibits hexokinase 2, an enzyme essential for cancer cell survival. This enzyme contributes to tumor proliferation by facilitating glycolytic flux and promoting lactic acid production in the tumor microenvironment.

How does Fenbendazole work?

*https://www.fenbendazole.org/fenbendazole-information/how-fenbendazole-works/

In our earlier work, we reported a potent growth-inhibitory activity of FZ[fenbendazole] caused partially by impairment of proteasomal function. Here, we show that FZ demonstrates moderate affinity for mammalian tubulin and exerts cytotoxicity to human cancer cells at micromolar concentrations. Simultaneously, it caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, expression of GLUT transporters as well as hexokinase (HK II) - a key glycolytic enzyme that most cancer cells thrive on. It blocked the growth of human xenografts in nu/nu mice model when mice were fed with the drug orally. The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity and may be evaluated as a potential therapeutic agent because of its effect on multiple cellular pathways leading to effective elimination of cancer cells.

Dogra, N., Kumar, A. & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. https://doi.org/10.1038/s41598-018-30158-6

….inhibiting tumors and targeting drug-resistant cancer cells through glycolysis inhibition.

Glucose, a primary energy source for tumor cells. Fenbendazole has been found to inhibit glucose uptake. Fenbendazole exhibits several other mechanisms contributing to its anti-cancer effects, primarily by disrupting energy metabolism.

Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Res. 2024;44(9):3725-3735. doi:10.21873/anticanres.17197

From the Fenbendazole Newsletter

A deep analysis of the clinical literature reveals that the fear of AO interference with chemotherapy is largely unsubstantiated by randomized trials. While the evidence regarding radiation is more complex, negative outcomes are often confounded by patient behaviors, such as smoking during treatment. Robust evidence supports the use of specific agents, notably melatonin, fish oil, and mushroom extracts (PSK), which have demonstrated significant survival benefits and reduced toxicity across various cancer types.

The Core Conflict: Conventional vs. Complementary Paradigms

The disagreement over supplements reflects differing underlying philosophies and interpretations of sparse clinical data.

• Conventional View: Based on the “first principle” that radiation and chemotherapy kill cancer cells by creating ROS. Antioxidants, by definition, neutralize ROS and are therefore presumed to reduce treatment efficacy.

• Complementary View: Argues that ROS damage to normal tissue causes the debilitating side effects of treatment. Furthermore, recent research suggests direct ROS-induced killing is only a minor part of the cytotoxic mechanism; the more critical factor is whether damage induces apoptosis (programmed cell death), a process regulated by proteins that can be favorably influenced by AOs.

• The “Catch-22” of Clinical Research: Conventional oncologists insist on evidence from randomized clinical trials before recommending supplements. However, because supplements cannot be patented, there is no financial incentive for the private sector to fund the necessary multi-million dollar trials. Consequently, complementary medicine often relies on a vast body of experimental literature (in vitro and in vivo).

Detailed Analysis of Antioxidant (AO) Evidence

Theories of Supplementation Strategy

Practitioners of integrative medicine differ on how AOs should be administered:

• High-Dose Synergy (Prasad): Argues that only high doses of specific AOs used in combination (e.g., Vitamin C, E, A, and beta-carotene) should be used, as they can inhibit cancer cell growth. Prasad recommends against low-dose multivitamins and agents that boost endogenous AOs (such as alpha-lipoic acid or N-acetylcysteine), fearing they may protect cancer cells.

• Toxicity/Division Balance (Conklin): Suggests that AOs may improve chemotherapy effectiveness because the rate of cancer cell division is inversely related to oxidative stress. Since chemotherapy only kills dividing cells, reducing oxidative stress may increase the population of cells vulnerable to treatment.

Clinical Trial Findings for Traditional AOs

A systematic review of 19 randomized trials comparing chemotherapy alone to chemotherapy plus AOs found no evidence of significant decreases in efficacy. In many instances, the AO groups showed increased survival and tumor response.

Specialized Treatment Agents

Melatonin: The Most Robust Clinical Evidence

Melatonin is a potent AO that also regulates circadian rhythms and stimulates the immune system.

• Survival Benefit: A meta-analysis of 10 randomized trials found a significant 1-year relative risk of death of 0.66 among those using melatonin.

• Lung Cancer: In a trial of 100 metastatic NSCLC patients, those receiving melatonin had a 40% one-year survival rate compared to 20% in the chemotherapy-only group. Toxicity was also significantly reduced.

• Glioblastoma: Patients receiving radiation plus 20 mg/day of melatonin showed significantly longer survival than those receiving radiation alone.

Amifostine: The Synthetic AO

Amifostine was developed to ameliorate radiation toxicity. Because it is metabolized more effectively in normal cells than cancer cells, it provides selective cytoprotection. Two meta-analyses concluded it significantly reduces radiation toxicity (mucositis, dysphagia) without reducing—and potentially improving—complete response rates.

Non-Anti-Oxidant Supplements

Polyunsaturated Fatty Acids (PUFAs/Fish Oil)

Fish oil components (EPA and DHA) are technically pro-oxidant because they generate ROS, but they also reduce inflammation and increase cell membrane permeability.

• Lung Cancer: Patients receiving EPA/DHA with chemotherapy had a 60% response rate, compared with 26% with chemotherapy alone.

• Breast Cancer: A Phase II trial showed that patients with high plasma DHA levels had a median survival of 34 months versus 18 months for those with low levels.

Mushroom Extracts (PSK)

PSK, an extract from the Coriolus Versicolor mushroom, is used for its immunological effects (stimulating T-cell activity and interferon production).

• Lung Cancer: Stage I patients using PSK had a 39% five-year survival rate vs. 22% for controls.

• Colorectal Cancer: PSK significantly improved three-year disease-free survival (81% vs. 69%).

Evaluation of Adverse Evidence

Conventional oncology’s opposition to AOs often cites three primary studies (Lawenda et al.), but closer examination reveals significant caveats:

1. The Lesperance Study (Breast Cancer): A trend toward interference was noted, but patients taking supplements were also more likely to reject radiotherapy, which is known to increase recurrence.

2. The Vitamin E/Oral Cancer Study: A trend toward worse survival in the Vitamin E group was noted. However, the “placebo” group received primrose oil (GLA), which has its own therapeutic benefits, and the Vitamin E group had more advanced stage III/IV cancers.

3. The Bairatti Study (Quebec Head-and-Neck): This large trial found a significant risk of recurrence and mortality for supplement users. However, re-analysis showed the deleterious effect occurred only in patients who smoked during radiation. For non-smokers, AOs did not negatively impact effectiveness and significantly reduced side effects.

Conclusion

There is no convincing clinical evidence that AO supplements generally interfere with chemotherapy. While the data for radiation is more debated, negative trends are frequently linked to confounding variables or specific behaviors like smoking.

Key Recommendations for Evaluation:

• Context Matters: Prudence is suggested for cancers where conventional treatment has a high success rate. However, for metastatic or resistant cancers where conventional treatment has a poor record, the potential benefits of supplements likely outweigh the hypothetical harms.

• Idiosyncratic Interactions: Some specific interactions must be avoided, such as Green Tea (EGCG) with the drug Bortezomib, as they bind and neutralize each other.

• Clinical Utility: Supplements such as melatonin, PSK, and fish oil have robust evidence supporting improved survival and quality of life by reducing the “slash, burn, and poison” toxicities associated with conventional oncology.

Source: The Role of Supplements (including Anti-Oxidants) in Cancer Treatment By Ben A. Williams University of California, San Diego Last Revised: July 12, 2014

Gastrointestinal cancers — colorectal, pancreatic, and hepatocellular — are among the most-discussed cancer types in online fenbendazole communities. On social media forums dedicated to repurposed drug research, questions about FBZ and colon cancer, pancreatic cancer, and liver cancer appear daily, driven in part by the extreme difficulty of treating these cancers with conventional approaches alone. Colorectal cancer is the third most diagnosed cancer worldwide and the second leading cause of cancer death. Pancreatic cancer carries a five-year survival rate under 12%. These grim statistics have driven patients and researchers alike to explore every available avenue, including benzimidazole antiparasitics.

This article synthesizes preclinical and early clinical evidence on fenbendazole and its benzimidazole relatives across three GI cancer types: colorectal cancer (CRC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC). We cover cell cycle arrest data from a 2022 AACR abstract, the unique finding that FBZ retains activity in 5-fluorouracil-resistant CRC cells via p53-independent ferroptosis, parbendazole + gemcitabine synergy in pancreatic cancer, and the UCSF liver cancer benzimidazole research. We also examine a 2026 safety case report from a patient with metastatic colon cancer that offers important lessons on monitoring and dose escalation.

⚠️ Educational Disclaimer

This article is for research and informational purposes only. It does not constitute medical advice and is not a substitute for professional oncology consultation. Always discuss any investigational protocol with your physician before making any treatment decisions.

Why GI Cancers Are at the Center of FBZ Research

The gastrointestinal tract is a particularly relevant site for benzimidazole pharmacology. Orally administered benzimidazoles, such as fenbendazole, are absorbed from the GI tract, meaning intestinal and colonic tissues are exposed to relatively higher local concentrations than many other tissues. This has led researchers to examine whether these drugs might be particularly relevant to GI-originating tumors.

Beyond pharmacokinetics, GI cancers share several biological features that align with FBZ’s known mechanisms of action:

High proliferative rate: Colorectal tumors are driven by rapid epithelial cell turnover, making cell cycle disruption especially relevant.

Chemotherapy resistance: Both colorectal (5-FU resistance) and pancreatic (gemcitabine resistance) cancers are notorious for developing resistance to first-line agents.

Metabolic dependency: GI cancers show strong reliance on glucose metabolism and microtubule-driven cell division — two pathways benzimidazoles target directly.

p53 mutations: Common in colorectal and pancreatic cancers, yet fenbendazole retains activity through p53-independent pathways, which is a significant mechanistic finding.

Read the full article: https://www.sanarelab.science/fenbendazole-colorectal-pancreatic-cancer/